Scarica l'app Stockscreener
10.26
9.38%
0.88
Dopo l'orario di chiusura:
10.00
-0.26
-2.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$9.38
Aprire:
$9.5
Volume 24 ore:
9.25M
Relative Volume:
2.57
Capitalizzazione di mercato:
$651.52M
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-4.4609
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
+21.71%
1M Prestazione:
-81.07%
6M Prestazione:
-69.80%
1 anno Prestazione:
-78.17%
Intervallo 1D:
$9.34
$10.59
Intervallo di 1 settimana:
$8.1773
$10.59
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
10.26 | 595.64M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire
Insider Stock Purchases: October 09, 2025 - Quiver Quantitative
MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative
Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com UK
BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile
Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire
MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with - GlobeNewswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
MLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results - Investing.com
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics Investors Should Contact Block - GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire
MLTX ACTIVE INVESTIGATION: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky Now - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
MoonLake Immunotherapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire
What is HC Wainwright’s Forecast for MLTX FY2025 Earnings? - Defense World
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Investors to Reach Out - ACCESS Newswire
MoonLake Immunotherapeutics (MLTX): Valuation in Focus After VELA HS Trial Setback and Market Scrutiny - simplywall.st
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga
Leading vs lagging indicators on MoonLake Immunotherapeutics performance2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on - The National Law Review
Ongoing MoonLake Immunotherapeutics (MLTX) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Combining price and volume data for MoonLake ImmunotherapeuticsRisk Management & Daily Profit Focused Screening - newser.com
What earnings revisions data tells us about MoonLake ImmunotherapeuticsSwing Trade & AI Driven Stock Price Forecasts - newser.com
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
MoonLake Immunotherapeutics results for Phase 3 VELA-1, VELA-2 trials - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Did MoonLake Immunotherapeutics (MLTX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
The week in pharma: action, reaction and insight – week to October 3 - The Pharma Letter
Is MoonLake Immunotherapeutics stock a buy before product launchesJuly 2025 Opening Moves & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-05 03:26:36 - newser.com
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results - MSN
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces - GlobeNewswire
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny - Yahoo Finance
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
MLTX Investor ALERT: Block & Leviton Investigating MoonLake Immunotherapeutics For Securities Fraud; Investors Should Contact The Firm To Potentially Recover Losses - ACCESS Newswire
Why MoonLake Immunotherapeutics (MLTX) Is Down 86.8% After Sonelokimab Phase 3 Trial Misses Key Goal - simplywall.st
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moonlake Immunotherapeutics Azioni (MLTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):